N
Nuvation Bio D
D
NUVB
5.06500
USD
0.27
(5.52%)
Market Closed
Volume
94,653
EPS
-0
Div Yield
-
P/E
-8
Market Cap
1,761,028,734
Title: Nuvation Bio
Sector: Healthcare
Industry: Biotechnology
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
